CONFERENCES

      International Conference on Alzheimer’s and Parkinson’s Diseases

      This is an annual conference that brings together experts in Alzheimer's and Parkinson's disease research, with topics ranging from basic biology to clinical trials. The conference is aimed at researchers, clinicians, and other professionals involved in the study and treatment of these diseases, and provides an opportunity to share knowledge and collaborate on new approaches to diagnosis and therapy.

      16th AD/PD Conference 2022

      Date

      Mar 15, 2022 - Mar 20, 2022

      Location

      Barcelona, Spain

      Online

      By merging together with the AAT-AD/PD™ Advances in Alzheimer’s Therapies Focus Meeting, AD/PD™ is now joint into an annual meeting, with a continuing focus on the ADVANCES IN SCIENCE & THERAPY of Alzheimer’s and Parkinson’s Diseases and related neurological disorders. A central theme of the 2022 conference will be to further advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers, in order to focus on driving successful collaborations among academia and industry, leading to the development of innovative therapies and ultimately providing for a better future for patients and families affected by neurodegenerative diseases.

      14th AD/PD Conference 2019

      Date

      Mar 26, 2019 - Mar 31, 2019

      Location

      Lisbon, Portugal

      With more than 3,500 participants, this conference combines distinct neurodegenerative diseases in one setting and examines their similarities and differences, with a strong focus is mechanisms of disease, prevention, and therapy.

      See related posters

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.